My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format

Send to:

Choose Destination

    Leukemia. 2008 Sep;22(9):1790-2. Epub 2008 Mar 20.

    TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.

    Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A.

    PMID: 18354492 [PubMed - indexed for MEDLINE]

    Publication Types, MeSH Terms, Substances

    Publication Types:

    MeSH Terms:

    Substances:

    LinkOut - more resources

    Full Text Sources:

    Libraries:

    Supplemental Content

    Click here to read

    Related articles

    Cited by 1 PubMed Central article

    All links from this record

    • Related Articles

      Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.

    • Substance (MeSH Keyword)

      PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

    • Cited in PMC

      Full-text articles in the PubMed Central Database that cite the current articles.

    Recent activity